People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk’s Wegovy.
Zepbound beats Wegovy rival in 1st head-to-head weight loss study
June 5, 2025
People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk’s Wegovy.
